243070.KQ
Huons Co., Ltd.
KOE · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 20,950.00
+0.24%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 607.8B | 620.8B | 590.2B | 552.0B | 492.4B |
| Cost of Revenue | 356.0B | 344.1B | 305.0B | 266.1B | 227.9B |
| Gross Profit | 251.7B | 276.6B | 285.2B | 285.9B | 264.5B |
| Operating Expenses | |||||
| R&D Expense | 33.8B | 41.8B | 35.7B | 32.9B | 36.5B |
| SG&A Expense | 162.1B | 152.6B | 166.8B | 193.3B | 186.4B |
| General & Admin Expense | 8.8B | 11.1B | 12.0B | 10.5B | 9.5B |
| Selling & Marketing Expense | 141.4B | 141.5B | 154.8B | 147.4B | 136.6B |
| Other Expenses | 48.8B | 36.7B | 43.1B | 39.3B | 2.2B |
| Total Operating Expenses | 233.0B | 231.1B | 245.5B | 226.1B | 225.1B |
| Cost and Expenses | 585.8B | 575.1B | 550.5B | 492.2B | 452.9B |
| Operating Income (EBIT) | 21.8B | 45.6B | 39.7B | 59.8B | 40.9B |
| Non-Operating | |||||
| Interest Income | 8.4B | 1.8B | 2.1B | 2.1B | 2.0B |
| Interest Expense | 8.1B | 6.3B | 3.2B | 2.5B | 3.2B |
| Net Interest Income | 355.5M | (4.4B) | (1.1B) | (395.9M) | (1.2B) |
| Other Non-Op Income/Expense | 287.6M | 3.2B | (1.7B) | 3.3B | (4.7B) |
| Non-Operating Income (excl Interest) | (9.4B) | — | (1.5B) | (5.8B) | (2.5B) |
| EBT (Pre-Tax Income) | 22.1B | 48.7B | 38.0B | 63.1B | 40.2B |
| Income Tax Expense | 4.9B | 6.5B | 9.0B | 12.7B | 17.6B |
| Bottom Line | |||||
| Net Income | 18.9B | 42.7B | 29.5B | 50.5B | 22.4B |
| Earnings from Cont. Ops | 17.2B | 42.2B | 29.1B | 50.4B | 22.5B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 18.9B | 42.9B | 29.5B | 50.5B | 22.4B |
| Per Share | |||||
| Basic EPS | ₩1,619 | ₩3,651 | ₩2,490 | ₩4,261 | ₩1,897 |
| Diluted EPS | ₩1,607 | ₩3,600 | ₩2,374 | ₩4,113 | ₩1,897 |
| Revenue Per Share | ₩50,731 | ₩51,817 | ₩49,838 | ₩46,602 | ₩41,618 |
| Shares | |||||
| Basic Shares Outstanding | 12.0M | 12.0M | 11.8M | 11.8M | 11.8M |
| Diluted Shares Outstanding | 12.0M | 12.0M | 12.1M | 12.3M | 11.8M |
| Profitability Metrics | |||||
| EBITDA | 54.7B | 72.6B | 61.4B | 83.8B | 60.1B |
| D&A | 32.9B | 27.0B | 20.9B | 18.2B | 16.7B |
| EBIT | 21.8B | 45.6B | 40.4B | 65.6B | 43.4B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026